![Michal Ayalon](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Michal Ayalon worked as Vice President of Research and Development at Kamada Ltd. from 2019 to 2022.
Prior to that, she held the same position at Galmed Pharmaceuticals Ltd. in 2015-2016.
In 2018-2019, she was Head of Research and Development at 89Bio Ltd. Ayalon received her undergraduate, graduate, and doctorate degrees from Tel-Aviv University.
Eerdere bekende functies van Michal Ayalon
| Bedrijven | Functie | Einde |
|---|---|---|
| KAMADA LTD. | Hoofd Techniek/Wetenschap/O&O | 28-02-2022 |
89Bio Ltd.
 89Bio Ltd. Pharmaceuticals: MajorHealth Technology Develops therapies and drugs for treatments of patients living with nonalcoholic steatohepatitis | Hoofd Techniek/Wetenschap/O&O | 01-01-2019 |
| GALMED PHARMACEUTICALS LTD. | Hoofd Techniek/Wetenschap/O&O | 01-01-2016 |
Opleiding van Michal Ayalon
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
22
Eerstegraads connecties
4
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Tel-Aviv University
 Tel-Aviv University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kamada Ltd.
 Kamada Ltd. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops and manufactures plasma-derived therapeutics products | Health Technology |
Galmed Pharmaceuticals Ltd.
 Galmed Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures aramchol for non-alcoholic steatohepatitis | Health Technology |
89Bio Ltd.
89Bio Ltd. Pharmaceuticals: MajorHealth Technology Develops therapies and drugs for treatments of patients living with nonalcoholic steatohepatitis | Health Technology |
